Colossal Biosciences, the pioneering genetic engineering technology company, has raised $200 million in a Series C funding round. The capital injection brings its valuation to $10.2 billion, marking progress in its mission to “revive” the woolly mammoth and other iconic species such as the dodo and thylacine .
About the financing round
The funding round was led by TWG Global , an investment firm co-founded by Mark Walter, owner of the Los Angeles Dodgers and co-owner of Chelsea FC, along with Thomas Tull, former CEO of Legendary Entertainment. Since its founding in 2021, Colossal has secured a total of $435 million in investments, establishing itself as a leader in the field of “de-extinction.”
[post_relacionado]Colossal uses advanced technologies such as CRISPR gene editing and induced pluripotent stem cells (iPSCs) to advance species recovery. One of its notable achievements includes the creation of a flock of Nicobar pigeons, close relatives of the dodo, to participate as germ cell donors in “de-extinction” experiments.
The woolly mammoth is back?
For the woolly mammoth , the company has developed genetic modifications using the DNA of Asian elephants , adapting it to Arctic conditions. In addition, the advances in the thylacine include editing 300 genes in a cell line from a related marsupial, representing a breakthrough in genetic manipulation.
Colossal’s work is not limited to “de-extinction.” The company is developing artificial womb technologies with potential applications in fertility treatments and species conservation. It also plans to commercialize biodiversity credits, an innovative mechanism similar to carbon credits , which could generate substantial revenues in the long term.
Allies in “de-extinction”
With laboratories in Dallas, Boston and Melbourne and collaborations with more than 16 universities, Colossal is establishing a global network to advance genomic science. The company also works with governments to apply its technologies to endangered species conservation programs.
Ben Lamm, CEO and co-founder of Colossal, said:
Investors have been optimistic in their desire to help us scale as quickly and efficiently as possible. This funding will grow our team, support the development of new technologies, expand our list of species in the process of de-extinction, and at the same time allow us to continue forward on our mission to make extinction a thing of the past.
Without a doubt, Colossal Biosciences continues to position itself as one of the most promising companies in the field of genetic science and conservation, opening up new possibilities for life on Earth.
Follow us on social media and don’t miss any of our posts!
YouTube LinkedIn Facebook Instagram X TikTok
Source: Colossal Biosciences
Photos: Shutterstock